Respiratory Syncytial Virus (RSV)

The study will include both participants who are otherwise healthy (ie, without underlying condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease (COPD), cardiovascular disease, other chronic diseases), with the exception of immunocompromised participants, presenting for medical care but not requiring hospitalization. The study will include a screening period (Day -1 to Day 1), a treatment Period (Day 1 to Day 8), and a follow-up period (Day 9 to Day 28). Safety evaluations will include adverse events, laboratory tests, electrocardiogram, vital signs, physical examination, and specific toxicities.

Therapeutic / Disease area: Infectious Disease, Influenza / Flu, Respiratory, Vaccines

Condition: Respiratory Infection

Locations: Blacktown (NSW), Kippa Ring (QLD), Wyong (NSW)

Commencement date: 01/07/2018

Status: Recruitment active




Recommend this trial to your friend

For privacy purposes, please note that your friend's details will not be sent to us and will not be stored in our database. Please be assured that we will not contact them.







I have read the Privacy Policy.

Register interest in future trials











I have read the Privacy Policy.